https://www.pharmaceutical-technology.com/news/fda-rmat-direct-biologics/
FDA grants RMAT designation to Direct Biologics’ EV drug for Covid-19
Apr 13, 2022 - The US FDA granted RMAT designation to Direct Biologics’ EV drug product, ExoFlo, for Covid-19-linked acute respiratory distress syndrome.